ORICORIC Pharmaceuticals, Inc.
What is the market doing?
No clear lean: in an uptrend, but a crowded short (+16% of shares).
In an uptrend, above its rising 50- and 200-day averages. Price is +18% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 22, 2026; selling is often routine (taxes, diversification).
A crowded short, settled Sep 30, 2026, more than a week of normal trading to cover, a crowded exit.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How ORIC is trading
ORIC Pharmaceuticals, Inc. is +9.0% over the past year while the S&P 500 is +16%: 7.0 points behind the market.
1-year return · S&P 500 +16%
- vs 200-day average
- +18%
vs 200-day average · a clear uptrend
- RSI (14)
- 57
RSI (14) · neutral
- Below its 52-week high
- 10%
Below its 52-week high
Details›
- Last close2026-10-23
- $13.17
- 1 monthS&P 500 −0.94%
- −0.19%
- 1 yearS&P 500 +16%
- +9.0%
- 5 yearsS&P 500 +86%
- −19%
- vs 50-day average$12.94
- +1.7%
- 52-week high
- $14.67
- 52-week low
- $7.47
- Annualised volatility
- 85%
| Year | Return |
|---|---|
| 2026 (year to date) | +61% |
| 2025 | +1.4% |
| 2024 | −12% |
| 2023 | +56% |
| 2022 | −60% |
| 2021 | −57% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 6 | 3 of 6 | +4.0% |
| Feb | 6 | 3 of 6 | −1.4% |
| Mar | 6 | 2 of 6 | −9.2% |
| Apr | 6 | 1 of 6 | −17% |
| May | 7 | 4 of 7 | +4.7% |
| Jun | 7 | 5 of 7 | +16% |
| Jul | 7 | 3 of 7 | +0.23% |
| Aug | 7 | 5 of 7 | +10% |
| Sep | 7 | 2 of 7 | −3.7% |
| Oct | 7 | 2 of 7 | −7.3% |
| Nov | 6 | 4 of 6 | +17% |
| Dec | 6 | 3 of 6 | +6.2% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Where the price stands
Its trend against the 50-day and 200-day averages, and the levels it keeps coming back to.
What it has returned
With dividends, year by year, month by month, and by calendar month on average.